the aid library

COVID-19 vaccine introduction toolkit
recommended

World Health Organization WHO (2021) C_WHO

The COVID-19 vaccine introduction toolbox equips all countries to prepare for and implement COVID-19 ... more

Plan de respuesta de emergencia Colombia - COVID -19

Reliefweb; OCHA Services; Acción contra el Hambre España (2020) C2

Accessed: 01.05.2020 El 11 de marzo de 2020 la OMS (Organización Mundial de la salud) ha declarado el CORONAVIRUS - COVID 19 como una pandemia mundial después que el número de afectados fuera ... more

COVID-19 ACAPS Resources

ACAPS (2020) C2

Global Level COVID-19: Vulnerability to containment measures (21/04/2020) COVID-19: Government ... more

COVID-19: Guidelines for communicating about coronavirus disease 2019 - A guide for leaders

Pan American Health Organisation PAHO (2020) C_WHO

Risk communication encompasses all the basics of health communication but differs in the need for speed and reliance on trust. At times of crisis, leaders are called on to provide a quick, sensitive and trustworthy response.

Recomendaciones para el tratamiento hospitalario de la COVID-19 en pacientes adultos ( Version 10, 2020)

G, Zambrano, E Salgato, F. M. Moyano et al. (2020) CC

Recommendations for in-patient management of COVID-19 in adult patients Version 10, November 2020.

Africa Joint Continental Strategy for COVID-19 Outbreak

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C2

Accessed: 02.04.2020

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID- ... 19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Covid-19 in Brazil in 2020: impact on deaths from cancer and cardiovascular diseases

Cordeiro Jardim, B.; et al. (2022) CC

Rev Saude Publica. 2022; 56: 22. Published online 2022 Apr 11. doi: 10.11606/s1518-8787.2022056004040

COVID-19 in Malawi: lessons in pandemic preparedness from a tertiary children’s hospital

Chaziya J, Freyne B, Lissauer S et al. (2021) CC

Archives of Disease in Childhood 2021;106:238-240.

Statement on the use of Dexamethasone for severely ill COVID-19 Patients

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C1

Africa Centers for Disease Control and Prevention (Africa CDC) is aware of the media releases of the preliminary results of a large randomized clinical trial conducted in the United Kingdom, which included dexamethasone, a corticosteroid, as one of the drugs used for the treatment of ... more

Recommendations to Member States to improve hand hygiene practices to help prevent the transmission of the COVID-19 virus: interim guidance (Chinese Version)

World Health Organization WHO (2020) C_WHO

就改进手卫生做法助力预防COVID-19病毒传播给会员国的建议

Additional Travel Advisory (I) for COVID-19 on Home Isolation

Government of India Ministry of Health & FW (2020) C2

More than 100 countries across the world now have reported cases of COVID-19. People traveling to these countries or people who have travelled abroad might possibly have come in contact with people ... more

Strategic Considerations for Mitigating the Impact of COVID-19 on Key Population-Focused HIV Programs

FHI 360; UNAIDS reliefweb (2020) C2

The COVID-19 pandemic has affected everyone, including key populations at higher risk of HIV. And the gains made against other infectious diseases, including HIV, are at risk of being reversed as a ... more

Directiva sanitaria para la vigilancia epidemiológica de la enfermedad por coronavirus (COVID-19) en el Perú

Ministerio de Salud, Peru (2021) CC

La presente establece los lineamientos y procedimientos para la vigilancia epidemiológica de COVID-19 en el país. Asimismo, los procedimientos, metodología e instrumentos para la vigilancia epide ... more

COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates

Sallam, M. (2021) CC

Interim Infection Prevention and Control Recommendations for Coronavirus Disease 2019 (COVID-19) in Health Care Settings

Ministry of Health, Kenya (2020) C2

Accessed: 02.05.2020 These interim IPC recommendations for health settings have been developed through the contributions of many individuals and institutions, such as the Centers for Disease Control-Kenya; ITECH; US Agency for International Development (USAID) Medicines, Technologies, and Pharmaceu ... more

Banso Tolonga – COVID-19 Rumor Tracking Bulletin

Internews (2021) CC

The project aims to build trust around COVID-19 vaccines to ensure greater access to and uptake in the vaccines through establishing healthy information ecosystems to address mis- and disinformation ... more

Migranten und Geflüchtete & Covid-19 in Deutschland
recommended

Rupp, N.; K. Geffert und S. Mauder MEDBOX (2020) CC

MEDBOX Issue Brief no.3